eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | non-alcoholic fatty liver disease |
| Comorbidity | C0011847|diabetes |
| Sentences | 88 |
| PubMedID- 22372457 | nafld is associated with obesity, diabetes, and insulin resistance, and is considered to be the liver manifestation of the metabolic syndrome. |
| PubMedID- 26147768 | Recent pilot studies investigated the effects of dipeptidyl peptidase-4 inhibitors on liver function and glucose metabolism in nafld with type 2 diabetes mellitus (dm). |
| PubMedID- 20842602 | Chronic disorders, such as obesity, diabetes, inflammation, non-alcoholic fatty liver disease and atherosclerosis, are related to alterations in lipid and glucose metabolism, in which peroxisome proliferator-activated receptors (ppar)alpha, pparbeta/delta and ppargamma are involved. |
| PubMedID- 23981342 | Insulin resistance is a main pathophysiological foundation of nafld, along with type 2 diabetes and even ms and cardiovascular diseases. |
| PubMedID- 25841911 | Majority of cases of hcc are due to chronic viral hepatitis b and c infections; however non-alcoholic fatty liver disease, associated with obesity and diabetes emerges as an important risk factor for hcc, in particular in the developed countries. |
| PubMedID- 24505484 | Indeed, the prevalence of nafld in patients with type 2 diabetes ranges from approximately 50 to 70% [2]–[4]. |
| PubMedID- 25966055 | Role of apn and tnf-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. |
| PubMedID- 23320150 | Evidence is now accumulating that nafld is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease (cvd). |
| PubMedID- 23954219 | Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 26356325 | Among nafld patients with diabetes, there was an increased tendency to have cirrhosis, as determined by biopsy, than nondiabetics (5 of 56 vs. 1 of 49, p=0.21). |
| PubMedID- 24402015 | Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. |
| PubMedID- 25885947 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 25044355 | After adjustments for potential confounders (ie, total cholesterol, diabetes, and length of hospital stay), nafld was no longer associated with a risk of a greater bmi increase [odds ratio (or) = 3.73 at 1 year (p = 0.11), or = 2.15 at 2 years (p = 0.34), and or = 2.87 at 5 years (p = 0.30)]. |
| PubMedID- 25303488 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 26339423 | Prognostic value of high sensitivity c-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. |
| PubMedID- 25961500 | Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. |
| PubMedID- 21278140 | The hazard ratio (hr) of incipient diabetes associated with nafld was estimated overall and separately in the normal fasting glucose (nfg) and ifg groups using cox proportional hazards analysis. |
| PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
| PubMedID- 26297218 | Conclusions: higher vpt associates with markers of liver fibrosis due to nafld in diabetes mellitus. |
| PubMedID- 26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. |
| PubMedID- 23671610 | We aim to investigate the relationships that fatty pancreas and nonalcoholic fatty liver disease (nafld) have with prediabetes and diabetes in a chinese population. |
| PubMedID- 24961024 | Gi: 52 patients diagnosed as nafld with diabetes mellitus type 2 or obesity or hyperlipedemia. |
| PubMedID- 22770479 | nafld is also associated with type 2 diabetes, cardiovascular disease[4,5] and insulin resistance[6] in muscle, adipose and liver[7]. |
| PubMedID- 24263777 | Thepresence of nafld in patients with type 2 diabetes has suggested nafld as a strongpredictor for cad32. |
| PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
| PubMedID- 20096896 | Recent evidence has suggested an association between microalbuminuria and ultrasound-diagnosed nonalcoholic fatty liver disease (nafld) in patients with diabetes and prediabetes. |
| PubMedID- 26573193 | Objective: to explore the relationship between socioeconomic status (ses) and non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24919218 | [advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus]. |
| PubMedID- PMC4020466 | The correct sentences should appear as given below.“nineteen hypertensive nafld patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 40 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months” in the “methods” section of the “abstract.”“nineteen hypertensive nafld patients with type 2 diabetes were randomly assigned to the telmisartan (t) group (receiving a standard dose of 40 mg once daily, n = 12) or the losartan (l) group (receiving a standard dose of 50 mg once daily, n = 7)” in section 2.2. |
| PubMedID- 26511621 | Conclusions: nafld was associated with diabetes risk among participants without metabolically at-risk. |
| PubMedID- 23997767 | In this randomized controlled study that examined the effect of telmisartan and losartan in improving steatosis in hypertensive nafld patients with type 2 diabetes, significant improvement in liver function was not observed in either group. |
| PubMedID- 21596453 | Serum fgf21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hscrp levels independently. |
| PubMedID- 21850244 | Although the simultaneous occurrence of type 2 diabetes with nafld or elevated liver enzymes is a frequent observation [7]–[10] and the role of insulin resistance has been reviewed [11], few studies with selected (clinical) populations have so far described the association between liver enzymes as surrogate measurements of fatty liver disease and “pre-diabetes” [12]–[16]. |
| PubMedID- 22969821 | Type 2 diabetes is associated with nonalcoholic fatty liver disease (nafld), and estimates of the prevalence of nafld in this group have varied, with the highest being 70% [1]. |
| PubMedID- 26573192 | [body mass index is a risk factor for new-onset non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus]. |
| PubMedID- 21886908 | Type 2 diabetes mellitus-induced hyperglycemia in patients with nafld and normal lfts: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. |
| PubMedID- 24667697 | The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 20625647 | Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors. |
| PubMedID- 23341703 | We compared the relationships of alcoholic fatty liver and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. |
| PubMedID- 23507799 | Therefore, nafld is strongly associated with type 2 diabetes mellitus and abdominal obesity. |
| PubMedID- 22008893 | Elderly nafld patients with diabetes, elevated serum ast, and especially thrombocytopenia (suggested to be associated with advanced liver fibrosis) should be monitored carefully during follow-up that includes using the apri to ensure early diagnosis and treatment of hcc. |
| PubMedID- 21196900 | Obesity and type ii diabetes, often associated with chronic nonalcoholic fatty liver disease, are emerging independent risk factors for hcc development. |
| PubMedID- 22087177 | nafld is frequently associated with obesity, diabetes mellitus and the metabolic syndrome. |
| PubMedID- 23843938 | Nonalcoholic fatty liver disease (nafld) is closely associated with type 2 diabetes mellitus. |
| PubMedID- 23332087 | This critical review of the published work aims to highlight the most recent basic and clinical data underlying the development of type 2 diabetes, in those with non-alcoholic fatty liver disease. |
| PubMedID- 25243967 | [analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus]. |
| PubMedID- 22927782 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. |
| PubMedID- 23663765 | Conclusion: serum hscrp levels may be predictive of development of nafld in individuals with type 2 diabetes mellitus. |
| PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
| PubMedID- 23226654 | Introduction: non-alcoholic fatty liver disease (nafld) is associated with type 2 diabetes (t2dm) and the metabolic syndrome, and can progress to chronic liver disease. |
Page: 1 2